<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="173228">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00840944</url>
  </required_header>
  <id_info>
    <org_study_id>EUDRACT 2007-003247-70</org_study_id>
    <nct_id>NCT00840944</nct_id>
  </id_info>
  <brief_title>A 4 Year Combination Therapy of Growth Hormone and (GnRH) Agonist in Children With a Short Predicted Height</brief_title>
  <acronym>ZomaTrip</acronym>
  <official_title>Efficacy and Safety of a 4 Year Combination Therapy of Growth Hormone and Gonadotropin- Releasing Hormone Agonist in Children With a Short Predicted Height.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Belgian Study Group for Pediatric Endocrinology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Belgian Study Group for Pediatric Endocrinology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Estrogens are responsible for the disappearance of growth cartilage in the long bones at the
      end of the pubertal growth spurt both in boys and in girls. It is therefore hypothesized
      that stopping pubertal development and hence estrogen production, will prolong and increase
      the pubertal growth spurt, especially when growth hormone is given concommitantly.

      Boys in early puberty, with a bone age between 11 and 13 years and a predicted adult height
      below 163 cm or girls in early puberty with a bone age between 10 and 12 years and a
      predicted height under 151 cm will be treated with triptorelin 3.75 mg and Zomacton growth
      hormone for 4 years.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2008</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>height</measure>
    <time_frame>6 - 8 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>bone density</measure>
    <time_frame>6 - 8 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Idiopathic Short Stature</condition>
  <arm_group>
    <arm_group_label>ZOMATRIP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GnRH agonist triptorelin plus somatropin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>no treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>somatropin</intervention_name>
    <description>somatropin 0.050 mg/kg/day</description>
    <arm_group_label>ZOMATRIP</arm_group_label>
    <other_name>growth hormone</other_name>
    <other_name>zomacton</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>triptorelin</intervention_name>
    <description>triptorelin 3.75 mg each month</description>
    <arm_group_label>ZOMATRIP</arm_group_label>
    <other_name>decapeptyl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult height prediction below -2.5 SD : 151 cm for girls and 164 cm for boys based on
             the vlaamse groeicurve 2004 (vub.ac.be/groeicurven)

          -  Pubertal: breast development at least M2 for girls and at least 4 ml of testicular
             volume for boys

          -  Bone age &gt;10 years but &lt; 12 years for girls and &gt; 11 but &lt; 13 years for boys

          -  Signed informed consent

        Exclusion Criteria:

          -  Adopted children ( different genetic background, lack of data on birth parameters and
             parents)

          -  Bone dysplasia or sitting height/ total height &gt; 2 SDS on standards by Gerver et al
             (see appendix)

          -  Chronic use of glucocorticoids

          -  Previous growth promoting therapy such as GH, sex steroids, oxandrolone,

          -  Known GH deficiency

          -  Chronic infectious disease

          -  Active rheumatic disease

          -  Previously diagnosed or currently suspected malignancy

          -  Sex steroid therapy

          -  Diabetes mellitus

          -  Renal insufficiency (serum creatinine &gt; 1.5 mg/dl)

          -  Hepatic disease ( liver test &gt; 4 fold upper limit of normality)

          -  Current congestive heart failure

          -  Inability to follow the study protocol

          -  Treatment with a non registered drug during the last 30 days before the moment of
             inclusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raoul P Rooman, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>BSGPE</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Raoul P Rooman, MD PhD</last_name>
    <phone>+32 3 821 4009</phone>
    <email>raoul.rooman@uza.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>Antwerp University Hospital</name>
      <address>
        <city>Edegem</city>
        <state>Antwerpen</state>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annick France, MD</last_name>
      <phone>+3238215549</phone>
      <email>annick.france@uza.be</email>
    </contact>
    <investigator>
      <last_name>Annick France, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hilde Dotremont, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virga Jesse Ziekenhuis</name>
      <address>
        <city>Hasselt</city>
        <state>Limburg</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guy Massa, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Guy Massa, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kinderziekenhuis UGent</name>
      <address>
        <city>Gent</city>
        <state>Oost Vlaanderen</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen Dewaele, MD PhD</last_name>
    </contact>
    <contact_backup>
      <last_name>Martine Cools, MD PhD</last_name>
      <email>martine.cools@ugent.be</email>
    </contact_backup>
    <investigator>
      <last_name>Kathleen Dewaele, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Martine COOLS, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Universitaire Reine Fabiola (HUDERF)</name>
      <address>
        <city>Brussels</city>
        <zip>1050</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Claudine Heinrichs, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sylvie TENOUTASSE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cecile BRACHET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kinderziekenhuis UZ Brussel</name>
      <address>
        <city>Brussel</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean De Schepper, MD PhD</last_name>
      <email>jean.deschepper@uzbrussel.be</email>
    </contact>
    <investigator>
      <last_name>Jean De Schepper, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU ND-des Bruy√®res</name>
      <address>
        <city>Liege</city>
        <zip>4030</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Pierre Bourguignon, MD,PhD</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Pierre Bourguignon, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie-Christine Lebrethon, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne-Simone PARENT, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <lastchanged_date>August 7, 2014</lastchanged_date>
  <firstreceived_date>February 10, 2009</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Belgian Study Group for Pediatric Endocrinology</investigator_affiliation>
    <investigator_full_name>Raoul Rooman</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>gonadotropin releasing hormone agonist</keyword>
  <keyword>growth hormone</keyword>
  <keyword>final height</keyword>
  <keyword>bone density</keyword>
  <keyword>puberty</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dwarfism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Triptorelin Pamoate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
